Contribution of the OC Sensor Immunoassay in Comparison to the Hemoccult II Guaiac-test in Organized Colorectal Cancer Screening
Overview
Authors
Affiliations
Colorectal cancer (CRC) is a major cause of cancer-related death of worldwide with high incidence and mortality rate, accessible to a screening program in France, first with guaiac- based fecal occult blood test (g-FOBT) then with fecal immunochemical tests (FIT), since 2015, because of better accuracy. The aim of our study was to compare the characteristics of screen-detected lesions in two successive CRC screening campaigns, using two different tests (Hemoccult II and OC Sensor) in the department of Maine-et-Loire, and to precise the performance of these tests [participation rate, detection rates (DR), positive predictive value (PPV)]. Participants, invited by CAP SANTE 49, with polyps or cancer at the colonoscopy after a positive screening test between 01/01/2013 and 31/12/2016 were included. A guaiac-based fecal occult blood test (g-FOBT) was used from January 2013 to December 2014 and a FIT was used from June 2015 to December 2016). 2575 participants, 642 in g-FOBT group and 1933 in FIT group had lesions. Participation rate was not different between tests (p = 0.104), whereas DR and PPV were statistically higher in FIT for all lesions (2.61, 95% CI [2.50-2.70] vs 0.93, 95% CI [0.90-1.00], p < 0.0001 and 64.84, 95% CI [63.10-66.60], 50.00, 95% CI [47.30-52.70], p < 0.0001 respectively). FIT detects more precancerous lesions (adenomas, p < 0.001, and advanced adenomas, p < 0.001) than g-FOBT but g-FOBT detects more serrated polyps (p = 0.025). AAs were more in right colon in FIT than g-FOBT (p = 0.035). No different participation rate was detected between FIT and g-FOBT but DR and PPV of all lesions was higher with FIT.
Innovative laboratory techniques shaping cancer diagnosis and treatment in developing countries.
Lawal A, Ogunniyi T, Oludele O, Olorunfemi O, Okesanya O, Ogaya J Discov Oncol. 2025; 16(1):137.
PMID: 39921787 PMC: 11807038. DOI: 10.1007/s12672-025-01877-w.
Koivogui A, Vincelet C, Abihsera G, Ait-Hadad H, Delattre H, Le Trung T World J Gastroenterol. 2023; 29(9):1492-1508.
PMID: 36998423 PMC: 10044857. DOI: 10.3748/wjg.v29.i9.1492.
Zhang M, Zhao L, Zhang Y, Jing H, Wei L, Li Z Front Oncol. 2022; 12:893183.
PMID: 35712520 PMC: 9195590. DOI: 10.3389/fonc.2022.893183.
Junca A, Tachon G, Evrard C, Villalva C, Frouin E, Karayan-Tapon L Cancers (Basel). 2020; 12(6).
PMID: 32517177 PMC: 7352444. DOI: 10.3390/cancers12061482.
Objectives, design and main findings until 2020 from the Rotterdam Study.
Ikram M, Brusselle G, Ghanbari M, Goedegebure A, Ikram M, Kavousi M Eur J Epidemiol. 2020; 35(5):483-517.
PMID: 32367290 PMC: 7250962. DOI: 10.1007/s10654-020-00640-5.